• Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

  • Sep 5 2024
  • Length: 14 mins
  • Podcast

Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

Listen for free

View show details

  • Summary

  • In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:

    • Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
    • Long-term safety observations for crizotinib and entrectinib
    • CNS activity of entrectinib and repotrectinib in patients with brain metastases
    • Repotrectinib activity in ROS1-TKI resistance mutations

    Program faculty:

    Jessica J. Lin, MD
    Attending Physician
    Massachusetts General Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Alice T. Shaw, MD, PhD
    Chief, Strategic Partnerships
    Attending Physician, Thoracic Oncology
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    Resources:
    To download the slides associated with this podcast discussion, please visit the program page.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available